Otsuka Pharmaceuticals and Proteus Digital Health released a joint statement on September 10 revealing the Food and Drug Administration (FDA) accepted their new drug application (NDA) for the first sensor-embedded version of Abilify for depression. (Drug Discovery and Davelopment)